Exicure Inc (XCUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Exicure Inc (XCUR) has a cash flow conversion efficiency ratio of -0.292x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.15 Million) by net assets ($3.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Exicure Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Exicure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Exicure Inc (XCUR) financial obligations for a breakdown of total debt and financial obligations.
Exicure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exicure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyngn Inc
NASDAQ:CYN
|
-0.174x |
|
Haily Group Bhd
KLSE:0237
|
0.173x |
|
Yonga Mobilya Sanayi ve Ticaret AS
IS:YONGA
|
-0.317x |
|
Sala @ Sathorn Property Fund
BK:SSPF
|
0.003x |
|
Ennogie Solar Group A/S
CO:ESG
|
0.032x |
|
OB Holdings Berhad
KLSE:0327
|
0.071x |
|
Celsius Resources Ltd
AU:CLA
|
-0.046x |
|
STS Group AG
XETRA:SF3
|
0.115x |
Annual Cash Flow Conversion Efficiency for Exicure Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Exicure Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see XCUR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.93 Million | $-8.55 Million | -2.179x | -407.10% |
| 2024-12-31 | $6.77 Million | $-2.91 Million | -0.430x | +87.42% |
| 2023-12-31 | $3.03 Million | $-10.36 Million | -3.417x | -42.99% |
| 2022-12-31 | $14.92 Million | $-35.66 Million | -2.390x | +22.91% |
| 2021-12-31 | $11.23 Million | $-34.82 Million | -3.100x | -385.53% |
| 2020-12-31 | $61.51 Million | $-39.27 Million | -0.638x | -4014.57% |
| 2019-12-31 | $80.75 Million | $1.32 Million | 0.016x | +101.75% |
| 2018-12-31 | $20.95 Million | $-19.49 Million | -0.930x | +6.12% |
| 2017-12-31 | $19.98 Million | $-19.79 Million | -0.991x | +51.98% |
| 2016-12-31 | $2.45 Million | $-5.05 Million | -2.063x | -208.20% |
| 2015-12-31 | $18.23 Million | $-12.20 Million | -0.669x | -- |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.